Education
About Us
Working with TipRanks
Follow Us
TMED - ETF AI Analysis
Top Page
T. Rowe Price Health Care ETF (TMED)
Rating:66Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered solid gains over the past three months, indicating strong momentum.
Focused Sector Exposure
With nearly all assets in health care, the ETF benefits from a clear focus on a historically resilient sector.
Reasonable Expense Ratio
The fund's expense ratio is relatively low compared to actively managed ETFs, making it cost-efficient for investors.
Negative Factors
Over-Concentration in Health Care
The ETF is heavily concentrated in the health care sector, which may limit diversification and expose investors to sector-specific risks.
Underperforming Key Holdings
Several top holdings, such as UnitedHealth and Intuitive Surgical, have lagged in performance, which could weigh on future returns.
Minimal Geographic Diversification
The ETF is overwhelmingly focused on U.S. companies, offering little exposure to international markets.
TMED vs. SPDR S&P 500 ETF (SPY)
AUM14.71M
RegionGlobal
Expense Ratio0.44%
Beta0.59
IssuerT. Rowe Price
Inception DateJun 11, 2025
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume4,409
30 Day Avg. Volume2,379
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
36.79Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering95
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TMED Summary
The T. Rowe Price Health Care ETF (TMED) is an actively managed fund that focuses on the health care sector, including companies involved in medical innovation, biotechnology, and health care services. It holds stocks like Eli Lilly & Co and UnitedHealth, giving investors exposure to some of the biggest names in the industry. This ETF might appeal to those looking for growth opportunities in a critical and expanding field, as health care is essential and constantly evolving. However, new investors should be aware that the fund’s performance is heavily tied to the health care sector, which can be impacted by regulatory changes or shifts in market demand.
How much will it cost me?The T. Rowe Price Health Care ETF (TMED) has an expense ratio of 0.44%, which means you’ll pay $4.40 per year for every $1,000 invested. This is higher than the average for ETFs because it is actively managed, with experts carefully selecting and adjusting the fund’s holdings to try to outperform traditional health care sector indices.
What would affect this ETF?The TMED ETF could benefit from advancements in biotechnology and medical innovation, as well as increasing global demand for health care services driven by aging populations and emerging markets. However, it may face challenges from regulatory changes, patent expirations, or economic downturns that could impact health care spending and the profitability of its top holdings. Additionally, fluctuations in interest rates could affect the broader market and investor sentiment toward health care stocks.
TMED Top 10 Holdings
The T. Rowe Price Health Care ETF (TMED) is leaning heavily on Eli Lilly, whose rising performance is fueled by strong revenue growth and a robust drug pipeline, making it the fund’s standout driver. Gilead Sciences and AbbVie are also contributing positively, with steady gains supported by strategic advancements in their portfolios. However, UnitedHealth is lagging, weighed down by challenges in managing medical costs and membership declines. With nearly all its holdings in the health care sector and a global reach, the fund is a focused bet on medical innovation, though its reliance on a few key names adds some concentration risk.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 13.67% | $2.18M | $928.57B | 24.82% | 72 Outperform | |
| UnitedHealth | 7.42% | $1.18M | $293.13B | -38.45% | 72 Outperform | |
| Abbott Laboratories | 4.57% | $729.08K | $210.84B | 7.37% | 73 Outperform | |
| Gilead Sciences | 3.88% | $620.43K | $148.09B | 31.35% | 78 Outperform | |
| Intuitive Surgical | 3.81% | $608.36K | $197.85B | 2.27% | 78 Outperform | |
| AbbVie | 3.75% | $598.28K | $394.11B | 29.14% | 66 Neutral | |
| Thermo Fisher | 3.71% | $592.91K | $211.55B | 7.38% | 72 Outperform | |
| ― | 3.30% | $526.32K | ― | ― | ― | |
| Danaher | 3.15% | $502.94K | $157.68B | -2.12% | 75 Outperform | |
| Becton Dickinson | 2.62% | $418.80K | $53.89B | -10.24% | 67 Neutral |
TMED Technical Analysis
Neutral
―
Price Trends
28.82
Positive
27.01
Positive
Market Momentum
0.23
Positive
52.05
Neutral
9.35
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TMED, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 29.62, equal to the 50-day MA of 28.82, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.23 indicates Positive momentum. The RSI at 52.05 is Neutral, neither overbought nor oversold. The STOCH value of 9.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TMED.
TMED Peer Comparison
Comparison Results
Performance Comparison
TMED
T. Rowe Price Health Care ETF
29.43
4.49
18.00%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
MEDX
Horizon Kinetics Medical ETF
―
―
―
JDOC
JPMorgan Healthcare Leaders ETF
―
―
―
BMED
Future Health ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents